Alterity Therapeutics (ATHE) Competitors $4.31 +0.03 (+0.70%) Closing price 03:59 PM EasternExtended Trading$4.32 +0.01 (+0.23%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. CRDF, IVVD, KALA, PYXS, EXOZ, ONCY, LFVN, SKYE, BMEA, and CGENShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Cardiff Oncology (CRDF), Invivyd (IVVD), KALA BIO (KALA), Pyxis Oncology (PYXS), eXoZymes (EXOZ), Oncolytics Biotech (ONCY), Lifevantage (LFVN), Skye Bioscience (SKYE), Biomea Fusion (BMEA), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Its Competitors Cardiff Oncology Invivyd KALA BIO Pyxis Oncology eXoZymes Oncolytics Biotech Lifevantage Skye Bioscience Biomea Fusion Compugen Alterity Therapeutics (NASDAQ:ATHE) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk. Does the media refer more to ATHE or CRDF? In the previous week, Cardiff Oncology had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for Cardiff Oncology and 2 mentions for Alterity Therapeutics. Cardiff Oncology's average media sentiment score of 0.45 beat Alterity Therapeutics' score of 0.37 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ATHE or CRDF? Alterity Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 178.42%. Cardiff Oncology has a consensus target price of $10.63, suggesting a potential upside of 346.43%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Cardiff Oncology 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, ATHE or CRDF? Alterity Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Do insiders & institutionals have more ownership in ATHE or CRDF? 2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Comparatively, 7.7% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is ATHE or CRDF more profitable? Alterity Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -9,344.14%. Alterity Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Cardiff Oncology -9,344.14%-77.94%-63.65% Which has preferable valuation and earnings, ATHE or CRDF? Alterity Therapeutics has higher earnings, but lower revenue than Cardiff Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$7.87MN/AN/ACardiff Oncology$680K232.86-$45.43M-$0.87-2.74 SummaryCardiff Oncology beats Alterity Therapeutics on 8 of the 13 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.91M$3.37B$6.10B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E RatioN/A21.7185.5527.59Price / SalesN/A477.40621.78138.47Price / CashN/A47.6737.7861.77Price / Book1.3910.1413.136.76Net Income-$7.87M-$52.31M$3.30B$275.88M7 Day Performance9.11%6.72%5.29%3.72%1 Month Performance-16.63%15.01%9.94%10.22%1 Year Performance226.52%29.34%87.78%35.86% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics2.5507 of 5 stars$4.31+0.7%$12.00+178.4%+228.8%$37.91MN/A0.0010Positive NewsAnalyst ForecastCRDFCardiff Oncology2.5951 of 5 stars$2.08+1.0%$10.63+410.8%-16.1%$137.04M$680K-2.3920Analyst ForecastIVVDInvivyd3.6802 of 5 stars$1.12flat$3.18+184.2%+76.9%$134.56M$46.21M-1.22100News CoverageAnalyst ForecastKALAKALA BIO4.1413 of 5 stars$2.05-89.2%$27.50+1,241.5%-69.3%$133.75M$3.89M-0.3030Analyst ForecastShort Interest ↑High Trading VolumePYXSPyxis Oncology1.9913 of 5 stars$2.20+2.8%$7.75+252.3%-25.0%$132.72M$2.82M-1.3760Analyst ForecastEXOZeXoZymes0.9639 of 5 stars$14.50-6.3%N/AN/A$129.84M$70K0.0029Positive NewsAnalyst ForecastONCYOncolytics Biotech1.5632 of 5 stars$1.41+9.3%$5.00+254.6%-3.6%$129.47MN/A-5.2230Analyst ForecastHigh Trading VolumeLFVNLifevantage4.3226 of 5 stars$9.76-4.2%$30.50+212.5%-20.8%$129.32M$228.53M13.19260News CoverageAnalyst ForecastSKYESkye Bioscience2.6797 of 5 stars$3.88-5.6%$14.75+280.2%-56.8%$127.36MN/A-3.6611News CoverageAnalyst DowngradeGap UpBMEABiomea Fusion3.4321 of 5 stars$2.06-1.9%$9.50+361.2%-82.3%$124.97MN/A-0.6850Trending NewsAnalyst ForecastOptions VolumeCGENCompugen1.4828 of 5 stars$1.44+4.3%$4.00+177.8%-0.6%$123.15M$27.86M-6.5570Analyst ForecastGap Up Related Companies and Tools Related Companies CRDF Competitors IVVD Competitors KALA Competitors PYXS Competitors EXOZ Competitors ONCY Competitors LFVN Competitors SKYE Competitors BMEA Competitors CGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored3 Major A.I. Threats That Could Upend the U.S. EconomyThe media's calling Artificial Intelligence a "revolution," but for many Americans, the real impact might actu...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
